FDA Places XNCR Trial On Hold ABIO Abuzz Mark Your Calendar For SRPT

FDA Places XNCR Trial On Hold, ABIO Abuzz, Mark Your Calendar For SRPT

00:15 EST 21 Feb 2019 | RTTNews

Today's Daily Dose brings you news about Achieve Life Sciences' progress in ORCA-1 trial; Agios Pharma's near-term regulatory catalyst; new development related to ARCA biopharma's PRECISION-AF pivotal study; financial outlook of Genomic Health and NuVasive; near-term clinical trial catalyst of Sarepta; and partial clinical hold on Xencor's phase I acute myeloid leukemia trial.

Original Article: FDA Places XNCR Trial On Hold, ABIO Abuzz, Mark Your Calendar For SRPT

More From BioPortfolio on "FDA Places XNCR Trial On Hold, ABIO Abuzz, Mark Your Calendar For SRPT"